Hemostemix Inc. (CVE:HEM – Get Free Report) fell 14.5% on Monday . The stock traded as low as C$0.27 and last traded at C$0.27. 438,482 shares were traded during trading, a decline of 36% from the average session volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Trading Down 14.5 %
The business’s 50-day simple moving average is C$0.11 and its 200-day simple moving average is C$0.08. The company has a market cap of C$23.09 million, a PE ratio of -13.25 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- What is the Shanghai Stock Exchange Composite Index?
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- 3 Best Fintech Stocks for a Portfolio Boost
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- How to Use the MarketBeat Dividend Calculator
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
